Brief: Design Therapeutics Reports Initial Results From Phase 1 Multiple-Ascending Dose Study Of Dt-216 For The Treatment Of Friedrich Ataxia
14/08/2023 21:56
Design Therapeutics Inc DSGN.O :
* DESIGN THERAPEUTICS REPORTS INITIAL RESULTS FROM PHASE 1
MULTIPLE-ASCENDING DOSE STUDY OF DT-216 FOR THE TREATMENT OF
FRIEDRICH ATAXIA
* DESIGN THERAPEUTICS - PLANS TO PROCEED WITH AN IMPROVED
DT-216
FORMULATION AND INITIATE A MULTIPLE DOSE PHASE 1 CLINICAL STUDY
IN SECOND HALF OF 2024
Source text for Eikon: ID:nGNX7551cV
Further company coverage: DSGN.O
Recent news on Design Therapeutics
See all newsDesign Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Design Therapeutics Q2 net loss narrower than expected
Brief: Design Therapeutics Q2 Basic EPS USD -0.32
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1